Search

Charles A Kallick

from Seattle, WA
Age ~95
Get Report
Also known as:
Charles Dr Kallick, Charles Arthur Kallick, Charles Kallia, Allick L Charles, Charles K
Related to:
Curran D Smith, 64Shari Bornstein, 62Aron BornsteinShirley L Bornstein, 55Herbert BornsteinYing F Liao
Connected to:
Blaine Kallicharan, 36Jayamohan Kallickal, 55Sarah J Kallick, 58Walter F Kallick, 77Jennifer R Kallie, 39Nadira B Kalliecharan, 49Richard S Kallien, 65Chadwick Kallies, 51Katherine A Kallies, 49Peter Kalligeros, 62

Charles Kallick Phones & Addresses

  • Seattle, WA
  • 400 E Randolph St APT 909, Chicago, IL 60601 (312) 650-5087
  • 400 Randolph St, Chicago, IL 60601 (312) 540-0617 (312) 650-5087
  • 16411 135Th St, Lemont, IL 60439 (630) 243-1024 (630) 257-5107

Professional Records

Medicine Doctors

Charles Kallick Photo 1

Charles John Kallick

View page
Specialties:
Psychiatry
Education:
Thomas Jefferson University (1958)

Public records

Vehicle Records

Charles Kallick

View page
Address:
16411 135 St, Lemont, IL 60439
Phone:
(630) 301-0050
VIN:
JTNBB46K773034525
Make:
TOYOTA
Model:
CAMRY HYBRID
Year:
2007

Resumes

Resumes

Charles Kallick Photo 2

Flight Attendant

View page
Location:
Phoenix, AZ
Industry:
Airlines/Aviation
Work:
Southwest Airlines
Flight Attendant
Education:
Arizona State University 2001 - 2005
Bachelors, Bachelor of Science, Business Management Green Valley High School 2001
Skills:
Customer Service
Aviation
Microsoft Word
Microsoft Excel
Strategic Planning
Sales
Charles Kallick Photo 3

Charles Kallick

View page
Location:
2502 northwest 92Nd St, Seattle, WA 98117
Industry:
Hospital & Health Care
Skills:
Flight Attendant
Languages:
English
Charles Kallick Photo 4

Charles Kallick

View page
Location:
Seattle, WA
Industry:
Medical Practice
Work:
Nonoe
Semi Retired

Business Records

Name / Title
Company / Classification
Phones & Addresses
Charles Kallick
Principal
Sphingomonas Research Partners, L.P
Business Services at Non-Commercial Site
16411 135 St, Lemont, IL 60439

Publications

Us Patents

Specific Bacterial Inclusions In Bone Marrow Cells Indicate Systematic Lupus Erthematosus, And Treatment For Lupus

View page
US Patent:
7820405, Oct 26, 2010
Filed:
Aug 2, 2006
Appl. No.:
11/461900
Inventors:
Charles A. Kallick - Lemont IL, US
Assignee:
Sphingomanas Research Partners, L.P. - Lemont IL
International Classification:
C12Q 1/04
C12Q 1/02
C12Q 1/00
US Classification:
435 34, 435 29, 435 4
Abstract:
A method for diagnosing for the presence of systemic lupus erythematosus (SLE) in a patient is disclosed. In accordance with this method, megakaryocytes present in bone marrow of a person suspected of having SLE are assayed for the presence of internal bacterial structures that specifically stain with an intercalating dye. The presence of those specifically stainable structures within the patient's megakaryocytes indicates that the patient has SLE. Treatment of an SLE patient with an antibiotic is contemplated. Treatment of a patient that has SLE comprises administering to that patient (i) an antibacterial amount of a rifamycin along with an antibacterial amount of a macrolide, (ii) an antibacterial amount of a tetracycline, or (iii) an antibacterial amount of a quinolone, or a mixture of two or more of i, ii and iii. The treatment is continued until the patient's megakaryocytes no longer contain specifically stainable structures, and until no further evidence of infection is present.

Treatment For Leukemia And Idiopathic Aplastic Anemia

View page
US Patent:
8642613, Feb 4, 2014
Filed:
Sep 17, 2009
Appl. No.:
12/561938
Inventors:
Charles A. Kallick - Chicago IL, US
Assignee:
Sphingomonas Research Partners, L.P. - Chicago IL
International Classification:
A61K 31/343
A61K 31/395
A61P 35/00
US Classification:
514279, 514299, 514312, 514450
Abstract:
A process for treating a patient with leukemia or an aplastic anemia having cells with inclusions that stain with anti-antibodies or antibodies to other or is disclosed. That process comprises administering to the patient (i) an antibacterial amount of a rifamycin, (ii) an antibacterial amount of a quinolone, or a mixture of (i) and (ii).

Diagnosis Of Systemic Lupus Erythematosus

View page
US Patent:
20060051778, Mar 9, 2006
Filed:
Mar 30, 2005
Appl. No.:
11/093805
Inventors:
Charles Kallick - Lemont IL, US
International Classification:
C12Q 1/68
G01N 33/554
G01N 33/569
US Classification:
435006000, 435007320
Abstract:
Diagnostic methods for the detection of SLE in a human body sample are disclosed. Nucleic acid hybridization and antibody-based methods derived from identification of or its 16S sequence are described.

Anaplasma Family Members Cause A Number Of Blood-Borne Diseases

View page
US Patent:
20130236897, Sep 12, 2013
Filed:
Mar 9, 2012
Appl. No.:
13/416827
Inventors:
Charles A. Kallick - Seattle WA, US
International Classification:
C12Q 1/68
US Classification:
435 612, 536 2433
Abstract:
A method of assaying for the presence of -infected blood cells or blood cell precursors from a patient is disclosed. The method comprises a) amplifying a nucleic acid-containing preparation of blood cells or blood precursor cells with a primer that contains a sequence of at least 12 consecutive bases of a polynucleotide of SEQ ID NOs:1-16 or an antisense sequence thereof; and detecting the presence of an amplified nucleic acid sequence. The presence of an amplified sequence indicates that the patient is suffering from -infected blood cells or blood cell precursors.

Anaplasma Family Members Cause A Number Of Blood-Borne Diseases

View page
US Patent:
20130236898, Sep 12, 2013
Filed:
Jun 11, 2012
Appl. No.:
13/493763
Inventors:
Charles A. Kallick - Seattle WA, US
International Classification:
C12Q 1/68
US Classification:
435 612, 536 2433
Abstract:
A method of assaying for the presence of -infected blood cells or blood cell precursors from a patient is disclosed. The method comprises a) amplifying a nucleic acid-containing preparation of blood cells or blood precursor cells with a primer that can be used to amplify a nucleic acid sequence that indicates that the patient is suffering from -infected blood cells or blood cell precursors.

Identification Of An Exogenous Intra-Erythrocytic Bacterium In Patients Having Systemic Lupus Erythematosus, And Treatment

View page
US Patent:
57955638, Aug 18, 1998
Filed:
Dec 13, 1996
Appl. No.:
8/763709
Inventors:
Charles A. Kallick - Lemont IL
Assignee:
Sphingomonas Research Partners, L.P. - Lemont IL
International Classification:
A61K 4900
A61K 3143
US Classification:
424 9361
Abstract:
Intra-erythrocytic exogenous bacterial structures or parasites seen by giemsa and phase contrast microscopy in several patients with systemic lupus erythematosus (SLE) and not in controls were identified as bacteria. Treatment of an SLE patient is contemplated with an antibacterial amount of a rifamycin in conjunction with an antibacterial amount of either a macrolide such as clarithromycin or a third generation cephalosporin such as cefpodoxime that is itself more preferably used in conjunction with an adjuvant amount of probenecid.

Diagnostic Method For Detection Of Systemic Lupus Erythematosus

View page
US Patent:
43293310, May 11, 1982
Filed:
Mar 13, 1980
Appl. No.:
6/129895
Inventors:
Charles A. Kallick - Lemont IL
International Classification:
G01N 3354
G01N 3358
C12Q 100
C12R 190
US Classification:
424 8
Abstract:
Systemic lupus erythematosus is diagnosed by contacting the blood serum of a patient with anaplasma antigen derived from a vertebrate infected by an organism of the genus Anaplasmataceae and thereafter contacting the antigen with an indicator for human immunoglobulin components.

Identification Of An Exogenous Intra-Erythrocytic Bacterium In Patients Having Systemic Lupus Erythematosus, And Treatment

View page
US Patent:
59723092, Oct 26, 1999
Filed:
Aug 11, 1998
Appl. No.:
9/131996
Inventors:
Charles A. Kallick - Lemont IL
International Classification:
A61K 4900
A61K 3143
US Classification:
424 9361
Abstract:
Intra-erythrocytic exogenous bacterial structures or parasites seen by giemsa and phase contrast microscopy in several patients with systemic lupus erythematosus (SLE) and not in controls were identified as bacteria. Treatment of an SLE patient is contemplated with an antibacterial amount of a rifamycin in conjunction with an antibacterial amount of either a macrolide such as clarithromycin or a third generation cephalosporin such as cefpodoxime that is itself more preferably used in conjunction with an adjuvant amount of probenecid.
Control profile
Charles A Kallick from Seattle, WA, age ~95 Get Report